Effects of structural modifications of daunorubicin on in vitro antileukemic activity

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5271-5277

  Stojak, Marta ^a   Mazur, Lidia ^a   Opydo Chanek, Małgorzata ^a   Łukawska, Małgorzata ^b   Oszczapowicz, Irena ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

Author keywords

Cell viability; Cell volume and count; Daunorubicin derivatives; Human acute leukemia cells; In vitro antileukemic activity

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DAUNORUBICIN; DAUNORUBICIN DERIVATIVE; FORMAMIDINODAUNORUBICIN HEXAMETHYLENEIMINE; FORMAMIDINODAUNORUBICIN MORPHOLINE; HEXAMETHYLENEIMINE DERIVATIVE; MORPHOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL COUNT; CELL SIZE; CELL VIABILITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84872529573     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Arcamone F, Animati F, Capranico G, Lombardi P, Pratesi G, Manzini S, Supino R and Zunino F: New developments in antitumor anthracyclines. Pharmacol Ther 76: 117-124, 1997.
2. Hortobagyi GN: Anthracyclines in the treatment of cancer. An overview. Drugs 54: 1-7, 1997.
3. Nadas J and Sun D: Anthracyclines as effective anticancer agents. Expert Opin Drug Discov 1: 539-548, 2006.
4. Oszczapowicz I, Wa̧sowska M, Oszczapowicz J, Owoc A, Dominiczak E, Wietrzyk J and Opolski A: New derivatives of anthracycline antibiotics, method of their synthesis, pharmaceutical agents containing them, and their use. Polish Patent 210494, 2005 (in Polish).
5. Wa̧sowska M, Oszczapowicz J, Oszczapowicz I and Owoc A: New method of synthesis of anthracycline antibiotic derivatives. Polish Patent Application P. 381654, 2006 (in Polish).
6. Kaspers GJL, Veerman AJP, Pieters R, Van Zantwijk I, Hählen K and Van Wering ER: Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leukemia Res 19: 175-181, 1995.
7. Ross DW: Cell volume growth after cell cycle block with chemotherapeutic agents. Cell Tissue Kinet 9: 379-387, 1976.
8. Ross DW: The nature of unbalanced cell growth caused by cytotoxic agents. Virchows Archiv B Cell Pathol 37: 225-235, 1981.
9. Ross DW: Volume increase in L5222 leukaemic cells following chemotherapy: Manifestation of leukaemic cell damage. Leukemia Res 5: 73-80, 1981.
10. Wa̧sowska M, Oszczapowicz I, Wietrzyk J, Opolski A, Madej J, Dzimira S and Oszczapowicz J: Influence of the structure of new anthracyclines antibiotics on their biological properties. Anticancer Res 25: 2043-2048, 2005.
11. Wa̧sowska M, Wietrzyk J, Opolski A, Oszczapowicz J and Oszczapowicz I: Effect of structural modification of anthracyclines on the ability to overcome drug resistance of cancer cells. Anticancer Res 26: 2009-2012, 2006.
12. Wa̧sowska-Łukawska M, Wietrzyk J, Opolski A, Oszczapowicz J and Oszczapowicz I: Biological properties of new derivatives of daunorubicin. In Vivo 21: 413-416, 2007.